Skip to main content
OpenTrials
Completed

NCT Number: NCT05882318

Effectiveness of eCoin at Sensory and Subsensory Amplitudes

The goal of this prospective, multi-center, double-blinded randomized controlled is to learn about effectiveness and QOL with eCoin at two different amplitude settings in subjects with urge urinary incontincence (UUI). The main question it aims to answer is:

* The reduction in UUI episodes per day on a 3-day voiding diary in both groups after 3 months of therapy

Participants will be implanted with the eCoin device and randomized to either a sensory or subsensory stimulation group and complete voiding diaries and patient reported-outcomes through 3 months of therapy. After 3 months, subjects will be unblinded and reprogramming will be offered. Subjects will be followed for an additional month to a total of 4 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Genesis Research, Downey, California, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Individual with diagnosis of overactive bladder with urgency urinary incontinence - daily UUI with a predominantly urgency component
  • Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or who have undergone percutaneous tibial nerve stimulation (PTNS).
  • Individual is determined to be a suitable surgical candidate by physician.

Key Exclusion Criteria:

  • Individual is not appropriate for eCoin therapy based upon the US FDA-approved IFU requirements.
  • Individual has predominantly stress urinary incontinence (greater than 1/3 of leaks on baseline diary are stress).
  • Individual has clinically significant bladder outlet obstruction.
  • Individual has an active urinary tract infection at time of enrollment or has had four or more symptomatic UTI's in the last 12 months.
  • Individual has significant lower urinary tract pain or has been diagnosed with interstitial cystitis or bladder pain syndrome that is actively being managed.
  • Individual has post void residual greater than 200 cc.
  • Individual has an active diagnosis of bladder, urethral, or prostate cancer.
  • Individual has had a prior anti-stress incontinence surgery within the last year.
  • Individual has uncontrolled diabetes mellitus (Hemoglobin A1C>7).
  • Individual is neutropenic or immune-compromised.
  • Individual has lower extremity pathology such as:
  • Previous surgery and/or significant scarring at the planned implant location
  • Ongoing dermatologic condition at the implant site, including but not limited to dermatitis and autoimmune disorders
  • Clinically significant peripheral neuropathy in the lower extremities
  • Pitting edema at the implant location (≥ 2+ is excluded)
  • Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg
  • Moderate to severe varicose veins
  • Open wounds or recent trauma
  • Arterial and/or vasculitis disease in the lower extremities
  • Chronic venous insufficiency with a history of skin change (hyperpigmentation, lipodermatosclerosis, ulceration) in the ankle region
  • Individual has neurogenic bladder dysfunction.
  • Individual is aware that he or she will need an MRI scan other than a head/neck/shoulder MRI during the study period.
  • Any condition that, in the investigator's opinion, would preclude participation in the study (e.g., comorbidity that places subject at increased risk for surgical intervention, medical condition that may increase the risk associated with study participation or may interfere with interpretation of study results, inability to adhere to the visit schedule, such as morbid obesity, clotting or bleeding disorder)

Treatment and study plan

eCoin Peripheral Neurostimulator System

Device

The eCoin device is a leadless, coin-sized tibial neurostimulator for treatment of urgency urinary incontinence. It emits a dome-shaped electrical field to deliver low-duty cycle stimulation to the tibial nerve. The device is to be implanted under local anesthetic in the lower leg, and once activated delivers automatic 30-minute treatment sessions without the need for patient management.

Primary outcomes

  1. Change in UUI Episodes Per Day

    Time frame: 3 months post-activation

    The primary endpoint is to explore the effect of two different eCoin amplitude settings on the change of UUI episodes per day on a 3-day voiding diary.

    A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline.

    A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

Secondary outcomes

  1. Change in UUI Episodes Per Day

    Time frame: 2 months post-activation

    Change in the number of urgency urinary incontinence episodes per day on a 3-day voiding diary.

    A negative number shows a reduction in UUI episodes which means symptoms have improved since baseline.

    A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

  2. Change in UUI Episodes Per Day

    Time frame: 4 months post-activation

    A secondary endpoint is to explore the change in UUI episodes per day on a 3-day voiding diary.

    A negative number shows a reduction in UUI episodes per day which means symptoms have improved since baseline.

    A positive number shows an increase in UUI episodes per day which means symptoms have worsened since baseline.

  3. Change in Overactive Bladder Health Related Quality of Life (HRQL)

    Time frame: 2 and 3 months post-activation

    Change from baseline in the patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey.

    Higher scores on the HRQL portion indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst).

    A positive change in score indicates an improvement in quality of life.

  4. Change in Overactive Bladder Health Related Quality of Life (HRQL)

    Time frame: 4 months post-activation

    Change from baseline in patient reported quality of life as assessed by the Health Related Quality of Life (HRQL) portion of the Overactive Bladder questionnaire (OABq) survey.

    Higher scores on the HRQL indicate better quality of life. The maximum HRQL domain score is 100 (best) and the minimum HRQL score is 0 (worst).

    A positive change in score indicates an improvement in quality of life.

Sponsors and collaborators

Lead sponsor

Valencia Technologies Corporation

Industry

Registry information

Official study title

Evaluating Effectiveness of Sensory and Subsensory Stimulation Amplitudes With eCoin® Tibial Nerve Stimulation in Urgency Urinary InContinence Episodes and Quality of Life

Acronym: ESSENCE

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
May 31, 2023
Registry last updated
Nov 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.